Abstract:Chronic infection of hepatitis B virus (HBV) remains a global public health problem and affects at least 240 million people worldwide. HBV is a small enveloped DNA virus belonging to the Hepadnaviridae family. The virus has a narrow host range, limited to humans and chimpanzees. In the nucleus of infected hepatocytes, the partially double-stranded DNA (rcDNA) HBV genome is converted to covalent closed circular DNA (cccDNA), which serves as the sole template for HBV transcription. HBV cccDNA exists as an episomal minichromosome in the nucleus, with a turnover rate that correlates with the mitosis or death of virus-infected hepatocytes. It is thus regarded as a primary molecular mechanism for viral persistence. In the past decade, significant progress has been made in HBV research and the related antiviral development. Sodium taurocholate co-transporting polypeptide (NTCP) has been identified as a receptor for HBV entry into hepatocytes. It was recently shown that HBV x (HBx), an enigmatic viral protein, achieves its regulatory function by hijacking the cellular DDB1-containing E3 ubiquitin ligase to target the Smc5/6 complex for degradation. Although still controversial, type I interferon has been implicated to either affect the epigenetic control of cccDNA minichromosome, or induce cytidine deaminases-mediated specific degradation of the episomal cccDNA. Of particular note, core protein allosteric modulator (CpAM) has been most widely investigated. These studies represent a new frontier in the development of antivirals against HBV infection. Despite continuing progress in HBV research, a complete cure of HBV infection is still not achievable. Current antiviral therapies with nucleos(t)ide analogs (NUC) and pegylated IFN-alpha can efficiently inhibit HBV replication, but the treatments fail to eliminate the preexisting cccDNA pool that is responsible for a viral rebound after therapy cessation. Therefore, it is widely held that cccDNA elimination is a prerequisite for complete cure of chronic HBV infection. To this end, it is essential to understand the mechanisms involved in cccDNA metabolism and transcriptional regulation. Studies of HBV cccDNA have often been hampered by the low copy number of cccDNA per cell and the lack of convenient techniques with high sensitivity and specificity for cccDNA detection. Development of appropriate experimental models is thus fundamental for HBV cccDNA studies. Herein, we reviewed recent advances in cell culture models for the study of HBV cccDNA, including models of HBV de novo infection and cccDNA biogenesis, cccDNA formation (rcDNA repair-related molecular events), HBV replicon-based transfection models to study established cccDNA, and the surrogate model of cccDNA produced from site-specific DNA recombination. Animal models to study HBV cccDNA will be further discussed by other authors in this issue. We hope this review may help clinicians and researchers who are interested in the study of cccDNA and antiviral development against HBV.

Chronic Hepatitis B Genotype C Mouse Model with Persistent Covalently Closed Circular DNA

A novel recombinant cccDNA-based mouse model with long term maintenance of rcccDNA and antigenemia

Recombinant Covalently Closed Circular DNA of Hepatitis B Virus Induces Long-Term Viral Persistence with Chronic Hepatitis in a Mouse Model

Recombinant Covalently Closed Circular Hepatitis B Virus DNA Induces Prolonged Viral Persistence in Immunocompetent Mice.

A spatiotemporally controlled recombinant cccDNA mouse model for studying HBV and developing drugs against the virus

In Vitro Experimental Models for the Study of Hepatitis B Virus Cccdna

In Vitro Cell Model and Mouse Model of HBV Cccdna

Metabolically Improved Stem Cell Derived Hepatocyte-Like Cells Support HBV Life Cycle and Are a Promising Tool for HBV Studies and Antiviral Drug Screenings

[Establishment of Hepatitis B Virus (HBV) Chronic Infection Mouse Model by in Vivo Transduction with a Recombinant Adeno-Associated Virus 8 Carrying 1. 3 Copies of HBV Genome (Raan8-1. 3HBV)].

Conversion of hepatitis B virus relaxed circular to covalently closed circular DNA is supported in murine cells

Establishment of Cell Culture Model and Humanized Mouse Model of Chronic Hepatitis B Virus Infection.

A CRISPR-based system to investigate HBV cccDNA biology

cccDNA Surrogate MC-HBV-Based Screen Identifies Cohesin Complex as a Novel HBV Restriction Factor

Therapies And Mechanisms Of West Nile Virus Encephalitis And Neurological Sequelae

Establishment of Cre-mediated HBV Recombinant Cccdna (rcccdna) Cell Line for Cccdna Biology and Antiviral Screening Assays

An HBV-tolerant immunocompetent model that effectively simulates chronic hepatitis B virus infection in mice.

HBV covalently closed circular DNA minichromosomes in distinct epigenetic transcriptional states differ in their vulnerability to damage

THE HEPATITIS B VIRUS AS A MOLECULAR MODEL FOR CHRONIC INFECTION: SYNTHESIS OF HEPATITIS B SURFACE AND E ANTIGENS IN MOUSE L CELLS TRANSFECTED WITH CLOSED CIRCULAR VIRAL DNA

Establishment and Primary Application of a Mouse Model with Hepatitis B Virus Replication.

Illuminating the Live-Cell Dynamics of Hepatitis B Virus Covalently Closed Circular DNA Using the CRISPR-Tag System

Adeno-Associated Virus Vector Mediated Delivery of the HBV Genome Induces Chronic Hepatitis B Virus Infection and Liver Fibrosis in Mice